Comparative Pharmacology
Head-to-head clinical analysis: LEVEMIR FLEXTOUCH versus TOUJEO SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVEMIR FLEXTOUCH versus TOUJEO SOLOSTAR.
LEVEMIR FLEXTOUCH vs TOUJEO SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that activates insulin receptors, promoting glucose uptake and inhibiting gluconeogenesis.
Insulin glargine is a long-acting human insulin analog that binds to the insulin receptor, activating cellular glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection, once or twice daily; starting dose 0.2-0.3 units/kg/day, titrate to target glycemic control.
Subcutaneous injection once daily at the same time each day. Starting dose in insulin-naïve patients: 0.2 units/kg or 10 units once daily, titrated to achieve glycemic targets. Maximum single dose: 80 units per injection.
None Documented
None Documented
Terminal half-life: approximately 5-7 hours (subcutaneous injection). The prolonged half-life relative to regular human insulin is due to reversible albumin binding, providing a flat, prolonged pharmacokinetic profile. Clinically, this supports once- or twice-daily dosing.
Terminal half-life: 19 hours (range 14–24 hours) after subcutaneous administration due to slow absorption from injection site.
Renal: approximately 50-70% of administered dose undergoes renal clearance as intact insulin; fecal: negligible (<10%). Insulin detemir is extensively metabolized in the liver (via dipeptidyl peptidase IV and other proteolytic enzymes) and the kidney, with metabolites excreted in urine.
Renal excretion of degradation products; minimal intact insulin in urine. Fecal elimination is negligible.
Category C
Category C
Long-Acting Insulin
Long-Acting Insulin